發(fā)布時(shí)間：2019-07-31 13:19

【摘要】：正手術(shù)、化療和放療是治療腫瘤的傳統(tǒng)方法,但大部分情況下患者都不能獲得理想的療效。近年來(lái),嵌合抗原受體修飾T細(xì)胞通過(guò)基因工程,賦予T細(xì)胞腫瘤靶向性、更強(qiáng)的殺傷活性和持久的生命力,并取得較好的臨床療效。然而,脫靶效應(yīng)、細(xì)胞因子風(fēng)暴等毒性效應(yīng)卻極大地限制了CAR-T細(xì)胞技術(shù)的應(yīng)用。本文就提高CAR-T細(xì)胞在治療惡性腫瘤臨床療效方面進(jìn)行如下綜述。1 CAR-T細(xì)胞的基本結(jié)構(gòu)和發(fā)展歷程
[Abstract]:Orthopedic surgery, chemotherapy and radiotherapy are traditional methods for the treatment of tumors, but in most cases patients can not achieve ideal results. In recent years, chimeric antigen receptor modified T cells have been genetically modified to give T cells tumor targeting, stronger killing activity and lasting vitality, and achieved good clinical efficacy. However, the off-target effect, cytokine storm and other toxic effects greatly limit the application of CAR-T cell technology. In this paper, the clinical efficacy of improving CAR-T cells in the treatment of malignant tumors is reviewed as follows. 1 the basic structure and development of CAR-T cells
【作者單位】： 安徽醫(yī)科大學(xué)附屬省立醫(yī)院檢驗(yàn)科;
【基金】：安徽省科技攻關(guān)項(xiàng)目(1604a0802072)資助
【分類號(hào)】：R730.51

【相似文獻(xiàn)】

相關(guān)期刊論文 前6條

1 孫瑋;腫瘤浸潤(rùn)淋巴細(xì)胞的殺傷機(jī)理及其抗原受體譜的偏移[J];國(guó)外醫(yī)學(xué)(免疫學(xué)分冊(cè));1996年05期

2 武國(guó)軍;T細(xì)胞抗原受體η亞單位低水平表達(dá)和低度種間保守性[J];國(guó)外醫(yī)學(xué)(免疫學(xué)分冊(cè));1993年05期

3 胡婉麗;趙Z，

本文編號(hào)：2521352